Aug 8 (Reuters) - Endo International PLC :
* PALADIN LABS ANNOUNCES HEALTH CANADA'S FILING ACCEPTANCE OF CENOBAMATE TABLETS AS AN ADJUNCTIVE THERAPY FOR THE MANAGEMENT OF PARTIAL-ONSET SEIZURES IN ADULTS WITH EPILEPSY
* PALADIN LABS - DECISION FROM HEALTH CANADA AS TO WHETHER CENOBAMATE TABLETS CAN BE MARKETED AND SOLD IN CANADA UNDER THIS NDS IS EXPECTED MID-2023
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.